Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Breadcrumb

  1. Home
9 May 2018

ORYZON Reports Financial Results and Corporate Update for the 1st Quarter 2018

8 May 2018

ORYZON receives approval in France to start ETHERAL: a Phase IIa clinical trial in Alzheimer’s Disease with ORY-2001

3 May 2018

ORYZON covered for the first time by a US investment bank: ROTH Capital Partners

29-31 May 2018

Foro MEDCAP2018

Madrid Stock Exchange Palace

Spain

24 May 2018

15th Anglonordic Life Science conference

County Hall, Riverside Building, Belvedere Road

London SE1 7PB

United Kingdom

14-16 May 2018

Bio€quity Europe 2018

Het Pand

Ghent

Belgium

1-2 May 2018

13th Annual Neurotech Investing & Partnering Conference

Renaissance Waterfront Hotel

MA

United States

27 April 2018

Oryzon to present at upcoming international conferences

9 April 2018

Oryzon to present at upcoming international conferences

4 April 2018

ORYZON receives approval to start ETHERAL: a Phase IIa clinical trial in Alzheimer’s Disease with ORY-2001

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 36
  • Page 37
  • Page 38
  • Page 39
  • Current page 40
  • Page 41
  • Page 42
  • Page 43
  • Page 44
  • Next page Next ›
  • Last page Last »
Subscribe to
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel